EVH Stock Up 42% after 10-Day Win Streak
Evolent Health (EVH) stock hit day 10 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 42% return. The company has gained about $548 Mil in value over the last 10 days, with its current market capitalization at about $1.3 Bil. The stock remains 3.4% above its value at the end of 2024. This compares with year-to-date returns of 5.4% for the S&P 500.
Comparing EVH Stock Returns With The S&P 500
The following table summarizes the return for EVH stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | EVH | S&P 500 |
|---|---|---|
| 1D | 3.3% | -0.1% |
| 10D (Current Streak) | 42.2% | 2.7% |
| 1M (21D) | 56.1% | 4.8% |
| 3M (63D) | 22.8% | 10.4% |
| YTD 2025 | 3.4% | 5.4% |
| 2024 | -65.9% | 23.3% |
| 2023 | 17.6% | 24.2% |
| 2022 | 1.5% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 182 S&P constituents with 3 days or more of consecutive gains and 8 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 65 | 4 |
| 4D | 88 | 0 |
| 5D | 3 | 2 |
| 6D | 1 | 2 |
| 7D or more | 25 | 0 |
| Total >=3 D | 182 | 8 |
Key Financials for Evolent Health (EVH)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $2.0 Bil | $2.6 Bil |
| Operating Income | $-21.1 Mil | $-14.1 Mil |
| Net Income | $-113.0 Mil | $-61.6 Mil |
Last 2 Fiscal Quarters:
| Metric | 2024 FQ4 | 2025 FQ1 |
|---|---|---|
| Revenues | $646.5 Mil | $483.6 Mil |
| Operating Income | $-1.3 Mil | $4,000 |
| Net Income | $-22.8 Mil | $-64.6 Mil |
While EVH stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.